Target intelligence / Profile preview

Alpha-glucosidase enzyme (intestinal brush border)

Molecular classification
Enzyme, Glycoside hydrolase family 31 (GH31), Alpha-glucosidase
01

Overview

Alpha-glucosidase is a hydrolytic enzyme complex found in the brush border of the small intestine, primarily composed of the membrane-bound glycosidases maltase-glucoamylase and sucrase-isomaltase[1][4]. It catalyzes the final step of carbohydrate digestion by cleaving terminal, non-reducing alpha-(1→4)-linked D-glucose residues from dietary disaccharides and oligosaccharides, producing free glucose for absorption[2][6]. These enzymes are essential for proper nutrient acquisition; dysfunction leads to malabsorption syndromes, while inhibition with drugs such as acarbose can therapeutically reduce postprandial hyperglycemia in diabetes mellitus[6]. Mutations in genes encoding these enzymes result in disorders such as congenital sucrase-isomaltase deficiency, leading to gastrointestinal symptoms due to poor carbohydrate digestion[1].

Other names
alpha-glucosidaseα-glucosidasealpha-D-glucoside glucohydrolasemaltase-glucoamylase (MGAM; intestinal subtype)sucrase-isomaltase (SI; intestinal subtype)glucosidoinvertaseα-1,4-glucosidase
02

Mechanism of action

competitive inhibition of alpha-glucosidase activity in the intestinal brush border, delaying carbohydrate breakdown and glucose absorption[6] reduced postprandial blood glucose increases, providing glycemic control in diabetes[6]

03

Biological functions

Digestion of dietary carbohydratesHydrolysis of terminal, non-reducing (1→4)-linked alpha-D-glucose residuesRelease of glucose from disaccharides and oligosaccharides
04

Disease associations

Diabetes mellitus (modulator of postprandial hyperglycemia)Congenital sucrase-isomaltase deficiency (CSID)Carbohydrate malabsorption syndromesIrritable bowel syndrome (IBS)Other gastrointestinal disorders linked to carbohydrate digestion
05

Safety considerations

gastrointestinal side effects (flatulence, diarrhea, abdominal discomfort) due to undigested carbohydrates reaching the colon[6]suboptimal efficacy compared to other anti-diabetic agents like metformin[6]
06

Interacting drugs

acarbose

3 more in the full profile.

07

Biomarkers

no established biomarker for patient selection; enzyme activity assays may monitor efficacy in research or rare disorders

Beyond the preview

Go deeper on Alpha-glucosidase enzyme (intestinal brush border).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-glucosidase enzyme (intestinal brush border).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call